Zenas BioPharma, Inc.

Company Overview

Business Model: Zenas BioPharma, Inc. is a clinical stage global biopharmaceutical company focused on developing and commercializing transformative immunology-based therapies for patients with autoimmune diseases. The Company has no products approved for commercial sale and has not generated revenue from product sales to date, with current revenue derived from licensing agreements.

Market Position: The Company's lead product candidate, Obexelimab, is a bifunctional monoclonal antibody in late-stage clinical development for multiple autoimmune indications. It is currently in a registration-directed Phase 3 trial for IgG4-related disease (where no approved products exist), and Phase 2 trials for relapsing multiple sclerosis and systemic lupus erythematosus. Zenas BioPharma, Inc. also has other product candidates, ZB002 and ZB004, in earlier clinical stages, and has out-licensed regional rights for ZB001 and ZB005.

Recent Strategic Developments:

• Redomiciliation & Public Listing: The Company redomiciled from the Cayman Islands to Delaware on August 2, 2023, and its common stock began trading on the Nasdaq Global Select Market under the symbol ZBIO on September 13, 2024.
• Obexelimab Clinical Progress: The registration-directed Phase 3 INDIGO trial for IgG4-related disease completed enrollment in November 2024, with topline data expected year-end 2025 and a Biologics License Application (BLA) submission planned for 2026. Phase 2 MoonStone (relapsing multiple sclerosis) and SunStone (systemic lupus erythematosus) trials were initiated in Q3 2024. The Company decided not to progress Obexelimab to a registration-directed trial for warm autoimmune hemolytic anemia.
• Strategic Licensing Agreements:
  • On January 24, 2025, Zenas BioPharma, Inc. exclusively sublicensed ZB001 for greater China to Zai Lab (Hong Kong) Limited, receiving a $10.0 million upfront fee and eligibility for up to $96.0 million in milestones and low to mid-single digit royalties.
  • On October 21, 2024, rights and obligations for ZB005 were transferred to Tenacia Biotechnology (Hong Kong) Co., Limited, with Zenas BioPharma, Inc. receiving a $5.0 million upfront fee and eligibility for up to $86.0 million in milestones.
  • An exclusive license agreement with Bristol-Myers Squibb Company for Obexelimab in Japan, South Korea, Taiwan, Hong Kong, Singapore, and Australia was established on August 30, 2023, including a $50.0 million upfront payment.

Geographic Footprint: The Company's principal executive offices are in Waltham, MA, with additional leased office space in Shanghai, PRC. Clinical trials for its lead candidate, Obexelimab, are conducted globally, spanning approximately 20 countries. Strategic partnerships extend its reach, with Bristol-Myers Squibb Company holding rights for Obexelimab in specific Asian and Australian territories, and Zai Lab (Hong Kong) Limited holding rights for ZB001 in greater China. The Company also has dedicated medical and commercial personnel in Europe.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: Not applicable (no product sales revenue).
• Operating Margin: Not applicable (operating at a loss).
• Net Margin: Not applicable (operating at a loss).

Investment in Growth:

• R&D Expenditure: $139.1 million (2782.8% of revenue)
• Capital Expenditures: Not explicitly detailed as a separate line item.
• Strategic Investments: Acquired in-process research and development was $0 in 2024, compared to $10.0 million in 2023, primarily related to license agreements.

Program Analysis

Obexelimab

Financial Performance:

• Research and Development Expenses: $94.6 million (2024), $25.4 million (2023)
• Key Growth Drivers: Enrollment completion of the registration-directed Phase 3 INDIGO trial for IgG4-related disease in November 2024, with topline data expected year-end 2025. Initiation of Phase 2 MoonStone trial for relapsing multiple sclerosis and Phase 2 SunStone trial for systemic lupus erythematosus in Q3 2024.

Product Portfolio:

• Obexelimab is a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb, inhibiting B cell activity without depleting them.
• Current and planned trials utilize a fixed 250 mg weekly self-administered subcutaneous injection.

Market Dynamics:

• IgG4-related disease (IgG4-RD): No approved products, estimated U.S. prevalence of approximately 20,000 patients. Phase 2 trial showed 80% of patients had a disease activity score decrease by ≥2 points, with 67% achieving complete remission.
• Relapsing multiple sclerosis (RMS): Estimated U.S. diagnosed prevalence of approximately 650,000 patients, a highly competitive market with numerous approved therapies.
• Systemic lupus erythematosus (SLE): Estimated U.S. diagnosed prevalence of approximately 150,000 patients, also a competitive market. A prior Phase 2 trial did not meet its primary endpoint for SLE disease activity, but showed a 17.3% absolute treatment difference in the ITT population.

ZB002 & ZB004

Financial Performance:

• Research and Development Expenses: $2.1 million (2024), $6.2 million (2023)
• Key Growth Drivers: ZB002 is in an ongoing Phase 1b Multiple Ascending Dose (MAD) study in rheumatoid arthritis. ZB004 has completed a Phase 1 Single Ascending Dose (SAD) study.

Product Portfolio:

• ZB002: An anti-TNFα monoclonal antibody with global rights. Preclinical studies demonstrated similar TNFα binding and inhibition to adalimumab, but with higher FcRn binding affinity and an extended (≥2-fold longer) half-life in mice.
• ZB004: A CTLA-4-Ig fusion protein with global rights. Preclinical studies showed approximately six-fold increased affinity to human CD80/CD86 compared to abatacept, and prophylactic efficacy in a collagen-induced arthritis model.

Partnered Regional Programs (ZB001 & ZB005)

Financial Performance:

• Research and Development Expenses: $6.7 million (2024), $6.7 million (2023)
• Key Growth Drivers: Strategic out-licensing agreements generating upfront payments and potential milestones.

Product Portfolio:

• ZB001: An anti-IGF-1R monoclonal antibody, exclusively sublicensed to Zai Lab (Hong Kong) Limited for greater China. Phase 1 SAD study in China completed (well tolerated), and Phase 1 MAD study in Chinese Thyroid Eye Disease (TED) patients completed (significant and rapid improvement).
• ZB005: Rights and obligations transferred to Tenacia Biotechnology (Hong Kong) Co., Limited.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: No share repurchases were disclosed.
• Dividend Payments: The Company has not paid cash dividends and has no current intention to pay dividends.
• Future Capital Return Commitments: Not disclosed.

Balance Sheet Position:

• Cash and Equivalents: $319.7 million (as of December 31, 2024)
• Total Debt: $0 (as of December 31, 2024), following the conversion of the Bristol-Myers Squibb Company Note into Series C Preferred Stock in May 2024.
• Net Cash Position: $319.7 million (as of December 31, 2024)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: No outstanding debt as of December 31, 2024.

Cash Flow Generation:

• Operating Cash Flow: -$119.7 million (2024)
• Free Cash Flow: Not explicitly detailed.

Funding Runway: The Company's cash, cash equivalents, and short-term investments of $350.9 million as of December 31, 2024, are expected to be sufficient to fund operations into Q4 2026. IPO Proceeds: The Company completed its IPO on September 16, 2024, generating $258.7 million gross proceeds and $234.3 million net proceeds.

Operational Excellence

Production & Service Model: Zenas BioPharma, Inc. does not own manufacturing facilities and relies on third-party contract manufacturing organizations (CMOs) for the supply of drug substance and drug product for preclinical and clinical trials.

Supply Chain Architecture: Key Suppliers & Partners:

• Manufacturing: WuXi Biologics (located in China) serves as a single third-party CMO for preclinical and clinical trial supply. New CMOs in the U.S. (not affiliated with WuXi Biologics) have been selected for additional commercial and clinical supply.
• Medical Device Components: Medical device components will utilize U.S. or EU device assembly facilities.

Facility Network:

• Headquarters: Waltham, MA - 30,102 square feet of leased office space, with the lease expiring April 30, 2026.
• International Office: Shanghai, PRC - 5,127 square feet of leased office space, with the lease extended to expire September 9, 2027.

Operational Metrics: Operational metrics such as capacity utilization or efficiency measures were not explicitly disclosed.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Zenas BioPharma, Inc. intends to build its own commercialization infrastructure in the U.S. and Europe if its products receive approval.
• Channel Partners: The Company plans to partner for commercialization in Asia and other geographies.
• Digital Platforms: Not disclosed.

Customer Portfolio: As a clinical-stage company, Zenas BioPharma, Inc. does not currently have commercialized products or a customer portfolio.

Geographic Revenue Distribution:

• China: 100% of total revenue in 2024 ($5.0 million), attributed to the Tenacia Biotechnology (Hong Kong) Co., Limited agreement.
• U.S. entity: 100% of total revenue in 2023 ($50.0 million), attributed to the Bristol-Myers Squibb Company agreement.
• Growth Markets: The Company has established partnerships for key growth markets, including the Bristol-Myers Squibb Company Territory (Japan, South Korea, Taiwan, Hong Kong, Singapore, Australia) for Obexelimab, and greater China for ZB001 through Zai Lab (Hong Kong) Limited.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biopharmaceutical industry is highly competitive, characterized by rapid technological advancements, extensive research and development, and significant regulatory hurdles. The Company operates in the autoimmune disease therapeutic area, which includes both established and emerging therapies.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• IgG4-related disease (IgG4-RD): No approved products currently. Competitors include Amgen Inc. (UPLIZNA, anti-CD19, BLA filed), Sanofi S.A. (BTK inhibitor, Phase 2), and off-label use of corticosteroids and immunosuppressants.
• Relapsing multiple sclerosis (RMS): A highly competitive market with numerous approved therapies from companies such as F. Hoffmann-La Roche Ltd. (Ocrevus), Novartis AG (Kesimpta, Extavia, Gilenya, Mayzent), TG Therapeutics Inc. (Briumvi), Sanofi S.A. (Lemtrada, anti-CD40/CD40L antibody Phase 3, BTK inhibitor Phase 3), Biogen (Tysabri, Avonex, Plegridy, Tecfidera, Vumerity), Bayer AG (Betaseron), Merck KGaA (Rebif, Mavenclad), Teva Neuroscience Inc. (Copaxone), Genzyme Corporation (Aubagio), Banner Life Sciences (Bafiertam), Cycle Pharmaceuticals Ltd. (Tascenso ODT), Janssen Pharmaceuticals, Inc. (Ponvory), and Bristol Myers Squibb Company (Zeposia). Immunic Therapeutics Inc. and AB Science also have Phase 3 candidates.
• Systemic lupus erythematosus (SLE): Approved therapies include GSK plc. (Benlysta), AstraZeneca plc. (Saphnelo), and RemeGen Co., Ltd. (Tai’ai, China only). Phase 3 competitors include UCB Biopharma SRL (anti-CD40L), Biogen Inc. (anti-BDCA2), F. Hoffmann-La Roche Ltd. (anti-CD20), Beijing Mabworks Biotech Co., Ltd. (anti-CD20, China only), Bristol Myers Squibb Company (TYK2 inhibitor), Idorsia Pharmaceuticals Ltd. (sphingosine-1-phosphate 1 receptor modulator), AbbVie Inc. (Janus kinase inhibitor), and Novartis AG (anti-BAFF-R antibody). Off-label use of antimalarials, corticosteroids, and immunosuppressants is also prevalent.
• ZB002 (anti-TNFα): Competes with five FDA-approved innovator anti-TNF programs (Humira, Enbrel, Remicade, Simponi, Cimzia) and numerous biosimilar anti-TNF programs.
• ZB004 (CTLA-4-Ig): Competes with two marketed CTLA-4-Ig fusion protein therapies (Orencia, Nulojix by Bristol Myers Squibb Company) and one Orencia biosimilar program in Phase 1.

Emerging Competitive Threats: Not explicitly detailed beyond direct competitors.

Competitive Response Strategy: Not explicitly detailed.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Product Development Risk: The Company has no products approved for commercial sale and has not generated revenue from product sales, relying on successful clinical development and regulatory approval of its product candidates.
• Competitive Landscape: The biopharmaceutical industry is highly competitive, with numerous established and emerging therapies for autoimmune diseases, posing significant challenges to market penetration and commercial success.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: The Company relies on a single third-party CMO, WuXi Biologics (located in China), for preclinical and clinical trial supply of drug substance and drug product, creating a concentration risk.
• Geopolitical & Regulatory Impact: The potential enactment of the BIOSECURE Act could restrict the ability to use certain Chinese biotechnology companies, including WuXi Biologics, which could disrupt the Company's supply chain.

Financial & Regulatory Risks

Market & Financial Risks:

• Funding & Profitability: The Company has incurred significant net losses ($157.0 million in 2024) and has an accumulated deficit of $387.4 million, indicating a reliance on external funding to support operations.
• Demand Volatility: Not explicitly mentioned, but inherent in the biopharmaceutical industry.

Regulatory & Compliance Risks:

• Extensive Regulation: The Company is subject to extensive U.S. and foreign regulations governing biologics development, approval, and commercialization.
• Policy Changes: Regulatory changes, such as provisions in the Biologics Price Competition and Innovation Act (BPCIA), Hatch-Waxman Amendments, data privacy laws (HIPAA, HITECH, CCPA, CPRA, GDPR), and the Inflation Reduction Act (IRA) impacting Medicare drug pricing, could significantly affect operations and profitability.
• Regulatory Uncertainty: The U.S. Supreme Court’s June 2024 decision in Loper Bright Enterprises v. Raimondo, overturning the Chevron doctrine, could increase regulatory uncertainty.

Geopolitical & External Risks

Geopolitical Exposure:

• Geographic Dependencies: Reliance on a China-based CMO and operations in China expose the Company to geopolitical risks and potential trade policy changes.
• Trade Relations: Potential impact of trade tensions and policy changes, such as the BIOSECURE Act, on manufacturing and supply chain.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Immunology-based Therapies: The Company focuses on developing precision immunology-based therapies for autoimmune diseases.
• Monoclonal Antibodies: Key product candidates include Obexelimab, a bifunctional monoclonal antibody, and ZB002, an anti-TNFα monoclonal antibody.
• Fusion Proteins: ZB004 is a CTLA-4-Ig fusion protein.
• Anti-IGF-1R Antibodies: ZB001 is an anti-IGF-1R monoclonal antibody.

Innovation Pipeline:

• Late-Stage Development: Obexelimab is in a registration-directed Phase 3 trial for IgG4-related disease, with topline data expected year-end 2025.
• Mid-Stage Development: Obexelimab is also in Phase 2 trials for relapsing multiple sclerosis and systemic lupus erythematosus.
• Early-Stage Development: ZB002 is in a Phase 1b study, and ZB004 has completed a Phase 1 study. ZB001 has completed Phase 1 studies in China.

Intellectual Property Portfolio:

• Patent Strategy: As of March 11, 2025, Zenas BioPharma, Inc. owns or exclusively in-licenses 14 patent families covering its product candidates, including 14 issued U.S. patents, 9 pending U.S. applications, 123 issued foreign patents, 4 pending PCT applications, and 41 pending foreign patent applications. Expected expiration dates range from 2027 through 2045.
• Licensing Programs: The Company has in-licensed technologies from Xencor, Inc. and Viridian Therapeutics, Inc., and has out-licensed regional rights to Bristol-Myers Squibb Company, Zai Lab (Hong Kong) Limited, and Tenacia Biotechnology (Hong Kong) Co., Limited.
• IP Litigation: Not presently a party to any legal proceedings that would have a material adverse effect.

Technology Partnerships:

• Strategic Alliances: Key partnerships include Xencor, Inc. (exclusive worldwide licenses for ZB002, ZB004, and Obexelimab), Bristol-Myers Squibb Company (exclusive license for Obexelimab in specific Asian and Australian territories), Zai Lab (Hong Kong) Limited (exclusive sublicense for ZB001 in greater China), and Tenacia Biotechnology (Hong Kong) Co., Limited (transfer of rights for ZB005).

Leadership & Governance

Executive Leadership Team

Board Composition: The Board of Directors includes Leon O. Moulder, Jr., Patricia Allen, James Boylan, Patrick Enright, Tomas Kiselak, Hongbo Lu, Ph.D., Jake Nunn, John Orloff, M.D., and Ting Xiao.

Human Capital Strategy

Workforce Composition:

• Total Employees: 130 full-time employees (as of February 28, 2025).
• Geographic Distribution: 14 employees are located in China, and the Company has dedicated medical and commercial personnel in Europe.
• Skill Mix: Not explicitly detailed.

Talent Management: Acquisition & Retention:

• Hiring Strategy: Not explicitly detailed.
• Retention Metrics: Not explicitly detailed.
• Employee Value Proposition: Not explicitly detailed.

Diversity & Development:

• Diversity Metrics: Not explicitly detailed.
• Development Programs: Not explicitly detailed.
• Culture & Engagement: No employees are represented by labor unions.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• Biologics Development & Approval: Zenas BioPharma, Inc. is subject to extensive U.S. and foreign regulations governing the development, approval, and commercialization of biological products.
• Orphan Drug Designation: Obexelimab for IgG4-related disease has received Orphan Drug Designation from the FDA.
• Data Exclusivity & Patent Term: The Biologics Price Competition and Innovation Act (BPCIA) provides 12 years of data exclusivity for reference biological products, and the U.S. Patent Term Restoration and Extension (Hatch-Waxman Amendments) allows for up to five years of patent term extension.
• Data Privacy: The Company is subject to various data privacy laws, including HIPAA, HITECH, CCPA, CPRA, and GDPR (EU and UK).

Trade & Export Controls:

• Export Restrictions: The potential enactment of the BIOSECURE Act could restrict the Company's ability to use certain Chinese biotechnology companies, including its current CMO, WuXi Biologics.

Legal Proceedings: The Company is not presently a party to any legal proceedings that would have a material adverse effect on its business.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The Company's effective income tax rate was -0.3% in 2024 and -0.8% in 2023.
• Geographic Tax Planning: The Company reports losses before taxes in both U.S. and non-U.S. jurisdictions.
• Tax Reform Impact: The Section 174 amendment, effective January 1, 2022, requires research and development expenses to be capitalized and amortized. The Inflation Reduction Act (IRA) includes provisions impacting Medicare drug pricing.

Deferred Tax Assets: As of December 31, 2024, the Company had total deferred tax assets of $90.9 million, primarily from net operating loss carryforwards ($29.6 million), capitalized research and development ($39.7 million), and research and development tax credits ($14.3 million). A full valuation allowance of $90.3 million was recorded against these deferred tax assets, resulting in a net deferred tax asset of $0. Net Operating Loss Carryforwards: As of December 31, 2024, the Company had $54.2 million of foreign net operating loss carryforwards, of which $47.8 million will carryforward indefinitely, with the remainder expiring between 2026 and 2028. All foreign NOL carryforwards are fully offset by valuation allowances.